These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 970227)

  • 1. Disopyramide in ventricular tachycardia.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1976; 200(3):209-13. PubMed ID: 970227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1976; 199(1-2):41-51. PubMed ID: 1251772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antiarrhythmic efficacy of disopyramide and mexiletine against stimulus-induced ventricular tachycardia.
    Breithardt G; Seipel L; Abendroth RR
    J Cardiovasc Pharmacol; 1981; 3(5):1026-37. PubMed ID: 6168848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of ventricular tachyarrhythmia with disopyramid phosphate].
    Steinbrunn W; Mattmann H; Enrico JF; Engel U
    Schweiz Med Wochenschr; 1980 Jun; 110(24):953-7. PubMed ID: 7414314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation.
    Lerman BB; Waxman HL; Buxton AE; Josephson ME
    Am J Cardiol; 1983 Mar; 51(5):759-64. PubMed ID: 6829435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous disopyramide phosphate and ventricular overdrive pacing in the termination of paroxysmal ventricular tachycardia.
    Camm J; Ward D; Washington HG; Spurrell RA
    Pacing Clin Electrophysiol; 1979 Jul; 2(4):395-402. PubMed ID: 95308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. Control by programmed ventricular stimulation.
    Manz M; Steinbeck G; Nitsch J; Lüderitz B
    Br Heart J; 1983 Mar; 49(3):222-8. PubMed ID: 6830659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction.
    Kus T; Sasyniuk BI
    J Pharmacol Exp Ther; 1976 Mar; 196(3):665-75. PubMed ID: 1263118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
    Vismara LA; Vera Z; Miller RR; Mason DT
    Am J Cardiol; 1977 Jun; 39(7):1027-34. PubMed ID: 326016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
    Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous disopyramide in myocardial infarction: a haemodynamic study.
    Marrott PK; Nairn PL; Hill PD; Turner G; Sharman J
    N Z Med J; 1983 Jan; 96(723):4-7. PubMed ID: 6571755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias.
    Camm J; Ward D; Spurrell RA
    Br J Clin Pharmacol; 1979 Nov; 8(5):441-9. PubMed ID: 508548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.
    Hulting J; Jansson B
    Eur J Clin Pharmacol; 1977 Jan; 11(2):91-9. PubMed ID: 320015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
    Kerr CR; Prystowsky EN; Smith WM; Cook L; Gallagher JJ
    Circulation; 1982 May; 65(5):869-78. PubMed ID: 6804107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.
    Cathcart-Rake WF; Coker JE; Atkins FL; Huffman DH; Hassanein KM; Shen DD; Azarnoff DL
    Circulation; 1980 May; 61(5):938-45. PubMed ID: 7363436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodynamic effects of intravenous disopyramide in heart failure.
    Jensen G; Sigurd B; Uhrenholt A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):167-73. PubMed ID: 1233215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
    Breithardt G; Haerten K; Seipel L
    Z Kardiol; 1976 Aug; 65(8):713-23. PubMed ID: 61664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.